Adjuvant S-1 Chemotherapy for Gastric Cancer and Peritoneal Wash

被引:0
作者
John Spiliotis
Odysseas Zoras
机构
[1] “METAXA” Cancer Memorial Hospital,Department of Surgery (B Unit)
[2] University of Crete,Department of General Surgery, University Hospital of Heraklion, Medical School
来源
World Journal of Surgery | 2011年 / 35卷
关键词
Gastric Cancer; Trastuzumab; Reverse Transcription Polymerase Chain Reaction; Peritoneal Recurrence; Metastatic Gastric Cancer;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:468 / 469
页数:1
相关论文
共 26 条
[1]  
Ito S(2010)Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR World J Surg 34 2083-2089
[2]  
Kodera Y(2010)Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance Ann Surg Oncol 17 14-17
[3]  
Mochizuki Y(2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-697
[4]  
Roukos DH(2010)Complete genome sequencing and network modeling to overcome trastuzumab resistance Pharmacogenomics 11 1039-1043
[5]  
Bang YJ(2009)CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16 2678-2681
[6]  
Cutsem E(2009)Current concerns and challenges towards tailored anti-angiogenic therapy in cancer Expert Rev Anticancer Ther 9 1413-1416
[7]  
Feyereislova A(2009)Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology Ann Surg 249 1067-1068
[8]  
Roukos DH(2009)Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice Ann Surg Oncol 16 1771-1782
[9]  
Ziogas D(2010)Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment Expert Rev Mol Diagn 10 541-545
[10]  
Roukos DH(2010)Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10 247-250